AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Eosinophilic Granulomatosis with Polyangiitis

Recent research efforts aimed at curing Eosinophilic Granulomatosis with Polyangiitis.

Last updated

Eosinophilic Granulomatosis with Polyangiitis

Overview

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune-mediated disease in which eosinophils—a type of white blood cell involved in allergy and inflammation—and inflammation of small-to-medium blood vessels can damage organs. It commonly develops in adults with asthma and chronic sinus or nasal-polyp disease, but can also affect nerves, skin, lungs, heart, kidneys, and the gastrointestinal tract. People whose disease is positive for antineutrophil cytoplasmic antibodies (ANCA) more often have nerve and kidney involvement, whereas ANCA-negative disease more often involves the heart and lungs. North American EGPA outcomes (pubmed.ncbi.nlm.nih.gov)

With timely treatment, EGPA has become a chronic, often relapsing illness rather than the uniformly life-threatening condition it once was; published cohorts report five-year survival above 90%, although accumulated organ damage, persistent asthma, infections, and relapses can still substantially affect quality of life. Recent prognosis study Current care aims to induce remission, prevent irreversible organ injury, and minimize corticosteroid exposure. For non-severe EGPA, guidelines support glucocorticoids plus the anti-interleukin-5 (IL-5) antibody mepolizumab; for severe organ-threatening disease, glucocorticoids plus cyclophosphamide or rituximab are recommended approaches. ACR/Vasculitis Foundation guideline (pmc.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research activity since 2020 has been meaningful but focused principally on achieving durable, steroid-sparing remission rather than eliminating the underlying predisposition to disease. The dominant questions are which immune pathway drives a given patient’s EGPA, whether eosinophil-targeted biologics can control both asthma and vasculitis, and how to select or combine treatments for ANCA-positive and ANCA-negative disease. As of August 8, 2026, no gene therapy, gene-editing, RNA therapy, cell therapy, or drug regimen has demonstrated a permanent cure for EGPA; the field is advancing toward more personalized long-term disease control. Updated EGPA treatment review (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

The clearest recent therapeutic advance is stronger targeting of the IL-5–eosinophil pathway. Benralizumab is an antibody against the IL-5 receptor alpha on eosinophils that promotes near-complete depletion of these cells. In the 140-participant MANDARA phase 3 trial, benralizumab was noninferior—but not superior—to mepolizumab for remission at weeks 36 and 48 in relapsing or refractory EGPA: remission occurred in 59% and 56% of participants, respectively. Complete withdrawal of oral glucocorticoids during weeks 48–52 occurred in 41% with benralizumab and 26% with mepolizumab. MANDARA trial (pubmed.ncbi.nlm.nih.gov)

This result translated into a regulatory milestone: on September 17, 2024, the U.S. Food and Drug Administration approved benralizumab for adult EGPA. It therefore offers a second FDA-approved eosinophil-directed biologic option alongside mepolizumab. This is an important improvement in disease management, particularly for reducing corticosteroid dependence, but it is not evidence of immune tolerance or a cure because participants generally continued maintenance treatment and some still relapsed. FDA orphan-drug approval record MANDARA trial (accessdata.fda.gov)

B-cell depletion remains a major complementary strategy because a subset of EGPA has ANCA-associated, antibody-mediated features. However, the 2025 REOVAS randomized phase 3 trial found that rituximab plus glucocorticoids was not superior to a conventional induction strategy of glucocorticoids alone or glucocorticoids plus cyclophosphamide in severe disease. At day 180, remission was reached by 63.5% of patients receiving rituximab and 60.4% receiving conventional treatment. This negative superiority result is valuable: it argues against assuming that an approach successful in other ANCA-associated vasculitides will cure, or uniformly improve, EGPA. REOVAS rituximab trial (pubmed.ncbi.nlm.nih.gov)

The most plausible future “disease-modifying” directions are not genetic correction but immune precision medicine: separating eosinophil-dominant disease from ANCA-associated vasculitic disease, identifying autoantibody targets, and eventually restoring antigen-specific immune tolerance without broad immunosuppression. A 2023 experimental study used patient serum, stimulated neutrophils and eosinophils, immunofluorescence, and proteomic target discovery to investigate possible granulocyte autoantigens, including myeloperoxidase and eosinophil-associated targets. These studies remain exploratory and have not yet produced a therapeutic vaccine, tolerogenic cell therapy, or curative intervention. Autoantigen discovery study (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

MANDARA (NCT04157348), sponsored by AstraZeneca, was a randomized, double-blind, active-controlled phase 3 study comparing benralizumab 30 mg with mepolizumab 300 mg every four weeks for 52 weeks in relapsing or refractory EGPA. Its noninferiority result underpinned the U.S. approval of benralizumab and established eosinophil depletion as a practical steroid-sparing treatment strategy rather than a curative one. MANDARA registry record MANDARA trial (clinicaltrials.gov)

The French Vasculitis Study Group’s REOVAS trial (NCT02807103) was a multicenter phase 3 trial of rituximab for remission induction. Its completed results did not show superiority over conventional treatment, reinforcing the need to identify the patients most likely to benefit from B-cell targeting. Earlier small-scale development included the phase 2 BITE study (NCT03010436), which evaluated benralizumab in 10 people with EGPA while monitoring symptoms and corticosteroid reduction; such small studies helped justify the subsequent larger MANDARA program. REOVAS rituximab trial BITE study record (pubmed.ncbi.nlm.nih.gov)

A major continuing research resource is the recruiting University of Pennsylvania longitudinal EGPA protocol, NCT00315380, within the Vasculitis Clinical Research Consortium. With estimated completion in December 2028, it follows people over time to connect clinical manifestations, treatments, biomarkers, and outcomes—essential infrastructure for designing future precision trials in a rare disease. University of Pennsylvania EGPA longitudinal study (clinicaltrials.gov)

Methodologies and Scientific Approaches

EGPA research increasingly combines longitudinal clinical cohorts with immune phenotyping. Investigators measure disease activity using tools such as the Birmingham Vasculitis Activity Score, track corticosteroid requirements and relapse, test ANCA status, quantify blood eosinophils, and assess organ-specific outcomes such as lung function, neuropathy, cardiac involvement, and sinus disease. In a recent phenotyping study, higher baseline blood eosinophil counts were associated with extrapulmonary systemic involvement, whereas lower counts were associated with a respiratory-limited phenotype, supporting—but not yet proving—the usefulness of eosinophils as a treatment-selection biomarker. EGPA phenotyping study (pubmed.ncbi.nlm.nih.gov)

Laboratory approaches include serum autoantibody screening, cellular immunofluorescence, proteomics, and comparisons of immune-cell pathways in ANCA-positive and ANCA-negative patients. These methods are intended to reveal whether EGPA is one disease or a set of related immune endotypes—biologically distinct forms that may require different therapies. Autoantigen discovery study North American EGPA outcomes (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Key clinical research centers include the University of Pennsylvania and the U.S. Vasculitis Clinical Research Consortium, the French Vasculitis Study Group and its network of French university hospitals, and AstraZeneca, which sponsored the MANDARA benralizumab program. Their work illustrates the field’s reliance on multicenter networks: EGPA is rare, so sufficiently powered trials and meaningful subtype analyses require international recruitment and long-term follow-up. University of Pennsylvania EGPA longitudinal study REOVAS rituximab trial MANDARA registry record (clinicaltrials.gov)

The Vasculitis Foundation is an important private funding source for the broader vasculitis field. Its 2026 Young Investigator Award offers up to $50,000 over two years for early-career projects in pathogenesis, biomarkers, epidemiology, and treatment; the foundation reports having awarded more than $3 million across more than 80 studies. Although these awards are not exclusively for EGPA, they support the pilot work needed to develop EGPA-specific studies and future federal funding applications. Vasculitis Foundation funding program Vasculitis Foundation research portfolio (vasculitisfoundation.org)

Strengths, Limitations, and Challenges

The field’s strongest achievement is that two biologic strategies now directly target the eosinophil pathway and can enable remission with substantially less corticosteroid exposure for many patients. Benralizumab’s phase 3 performance and FDA approval expand choice, while the rituximab trial provides unusually rigorous evidence about where B-cell depletion does and does not add benefit. MANDARA trial FDA orphan-drug approval record REOVAS rituximab trial (pubmed.ncbi.nlm.nih.gov)

The central limitation is heterogeneity: EGPA can be driven by eosinophilic tissue inflammation, ANCA-associated vasculitis, or both, while trials often enroll relatively small and clinically mixed populations. Remission is also not cure—ongoing biologic treatment may be needed, severe cardiac, kidney, nerve, or gastrointestinal disease remains difficult to study, and prolonged corticosteroid or immunosuppressant exposure can cause serious harms. Biomarkers such as eosinophil count and ANCA status are useful clues but are not yet sufficiently validated to assign every patient to an optimal therapy. EGPA phenotyping study ACR/Vasculitis Foundation guideline (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

EGPA is not close to a proven cure as of August 8, 2026, but the outlook for better long-term control is improving. Milestones to watch are extended follow-up from benralizumab-treated cohorts, biomarker-guided trials that separately test eosinophilic and vasculitic endotypes, better evidence for treatment of severe organ-threatening disease, and translational studies that can move from identifying disease-specific autoantigens toward selective immune tolerance. A genuine cure would require durable treatment-free remission without recurrent eosinophilic inflammation or vasculitis, and current studies have not yet shown that outcome. University of Pennsylvania EGPA longitudinal study Autoantigen discovery study (clinicaltrials.gov)

References

Don't see your disease? Request a report